Funds › Blue Owl Capital Holdings LP
Blue Owl Capital Holdings LP
13F for Q3 2026, filed Nov 13, 2026. 73 positions worth $547.6M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Latest report
Q3 2026
filed Nov 13, 2026
Reported value
$547.6M
−$116.9M (17.6%) vs Q2 2026
Positions
73
71 in Q2 2026
Top 10 share
77.4%
of reported value
CheckedEach line's price per share is checked against other managers' reports of the same stock. Unit mix-ups are corrected. Reports no fix can rescue are left out.
Clean
prices match other managers' reports
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Blue Owl Capital Holdings LP in the latest 13F quarter?
Using 13F.ai, how has Blue Owl Capital Holdings LP's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Blue Owl Capital Holdings LP's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q3 2026
Largest first. Common shares only; puts and calls are under All positions.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | SPCX Space Exploration Technologies Corp. | 923,218 | $139.3M | 25.4% | -34.0% | 13F ↗ |
| 2 | AKTS Aktis Oncology, Inc. | 3.34M | $65.1M | 11.9% | +8.9% | 13F ↗ |
| 3 | LTGO Latigo Biotherapeutics, Inc. · Inc Com | 3.60M | $60.1M | 11.0% | New | 13F ↗ |
| 4 | LRMR Larimar Therapeutics, Inc. | 9.92M | $31.7M | 5.8% | +8.3% | 13F ↗ |
| 5 | ETRA Electra Therapeutics, Inc. | 2.61M | $29.4M | 5.4% | New | 13F ↗ |
| 6 | NCDL Nuveen Churchill Direct Lending Corp. | 2.14M | $24.1M | 4.4% | Unchanged | 13F ↗ |
| 7 | CGEM Cullinan Therapeutics, Inc. | 1.40M | $21.5M | 3.9% | -9.1% | 13F ↗ |
| 8 | OBDC Blue Owl Capital Corporation | 2.05M | $21.5M | 3.9% | Unchanged | 13F ↗ |
| 9 | OBX Obsidian Therapeutics, Inc. | 1.48M | $20.4M | 3.7% | New | 13F ↗ |
| 10 | SGMT Sagimet Biosciences Inc. | 1.13M | $11.1M | 2.0% | -10.7% | 13F ↗ |
| 11 | DELL Dell Technologies Inc. | 19,342 | $10.4M | 1.9% | -41.3% | 13F ↗ |
| 12 | HLLY Holley Inc. | 4.38M | $10.3M | 1.9% | Unchanged | 13F ↗ |
| 13 | CNDT Conduent Incorporated | 5.04M | $7.9M | 1.4% | Unchanged | 13F ↗ |
| 14 | FISN Deep Fission, Inc. | 1.33M | $6.8M | 1.2% | Unchanged | 13F ↗ |
| 15 | AQST Aquestive Therapeutics, Inc. | 1.39M | $6.4M | 1.2% | +47.5% | 13F ↗ |
| 16 | IMMX Immix Biopharma, Inc. | 602,047 | $6.3M | 1.1% | +37.6% | 13F ↗ |
| 17 | MPLT MapLight Therapeutics, Inc. | 556,371 | $5.7M | 1.0% | -23.8% | 13F ↗ |
| 18 | MANE Veradermics, Incorporated | 45,000 | $5.5M | 1.0% | New | 13F ↗ |
| 19 | IMA ImageneBio, Inc. | 1.14M | $5.2M | 0.9% | +23.7% | 13F ↗ |
| 20 | IRD Opus Genetics, Inc. | 969,605 | $4.7M | 0.9% | New | 13F ↗ |
| 21 | CRVS Corvus Pharmaceuticals, Inc. | 358,600 | $4.1M | 0.8% | -41.1% | 13F ↗ |
| 22 | RZLT Rezolute, Inc. | 935,000 | $3.9M | 0.7% | New | 13F ↗ |
| 23 | ARTV Artiva Biotherapeutics, Inc. | 529,542 | $3.8M | 0.7% | -39.4% | 13F ↗ |
| 24 | Cybin Inc | 288,282 | $3.5M | 0.6% | +381% | 13F ↗ |
| 25 | ACHV Achieve Life Sciences, Inc. | 412,654 | $3.3M | 0.6% | New | 13F ↗ |
| 26 | PCOR Procore Technologies, Inc. | 64,030 | $3.3M | 0.6% | New | 13F ↗ |
| 27 | CMPX Compass Therapeutics, Inc. | 3.15M | $3.3M | 0.6% | -13.0% | 13F ↗ |
| 28 | PVLA Palvella Therapeutics, Inc. | 23,003 | $3.2M | 0.6% | -36.6% | 13F ↗ |
| 29 | ZURA Zura Bio Limited | 735,000 | $3.1M | 0.6% | New | 13F ↗ |
| 30 | LENZ LENZ Therapeutics, Inc. | 781,722 | $3.0M | 0.5% | +3.3% | 13F ↗ |
| 31 | STWD STARWOOD PROPERTY TRUST, INC. Starwood Property Trust Inc. | 196,355 | $2.7M | 0.5% | Unchanged | 13F ↗ |
| 32 | PYXS Pyxis Oncology, Inc. | 1.00M | $2.3M | 0.4% | New | 13F ↗ |
| 33 | VRDN Viridian Therapeutics, Inc. | 100,000 | $2.1M | 0.4% | -61.5% | 13F ↗ |
| 34 | NTSK Netskope, Inc. | 97,148 | $1.7M | 0.3% | New | 13F ↗ |
| 35 | TTAN ServiceTitan, Inc. | 25,360 | $1.7M | 0.3% | New | 13F ↗ |
| 36 | FA First Advantage Corporation | 88,665 | $1.6M | 0.3% | New | 13F ↗ |
| 37 | ELDN Eledon Pharmaceuticals, Inc. | 566,509 | $1.4M | 0.3% | Unchanged | 13F ↗ |
| 38 | WW WW International, Inc. | 71,277 | $1.1M | 0.2% | -15.5% | 13F ↗ |
| 39 | ADCT ADC Therapeutics SA | 733,568 | $895.0K | 0.2% | Unchanged | 13F ↗ |
| 40 | USDEW StablecoinX Inc. · *W Exp 06/25/203 | 167,795 | $839.0K | 0.2% | -32.9% | 13F ↗ |
| 41 | MRKR Marker Therapeutics, Inc. | 554,250 | $593.0K | 0.1% | Unchanged | 13F ↗ |
| 42 | FLD Fold Holdings, Inc. | 856,632 | $454.0K | 0.1% | Unchanged | 13F ↗ |
| 43 | NIOBW NioCorp Developments Ltd. · *W Exp 03/17/202 | 268,280 | $201.2K | <0.1% | Unchanged | 13F ↗ |
| 44 | PIPR Piper Sandler Companies | 2,428 | $160.2K | <0.1% | Unchanged | 13F ↗ |
| 45 | CAI Caris Life Sciences, Inc. | 4,711 | $144.3K | <0.1% | Unchanged | 13F ↗ |
| 46 | RZLVW Rezolve AI PLC · *W Exp 08/15/202 | 235,121 | $129.3K | <0.1% | Unchanged | 13F ↗ |
| 47 | ET Energy Transfer LP · Com Ut Ltd Ptn | 5,326 | $105.3K | <0.1% | Unchanged | 13F ↗ |
| 48 | ENGNW enGene Therapeutics Inc. · Spac Combination | 511,177 | $102.3K | <0.1% | Unchanged | 13F ↗ |
| 49 | VOD Vodafone Group Plc · ADR | 5,371 | $86.8K | <0.1% | Unchanged | 13F ↗ |
| 50 | BNAIW Brand Engagement Network Inc. · Spac Combination | 746,953 | $37.3K | <0.1% | -48.6% | 13F ↗ |
Showing the top 50 of 73 positions. Premium lists every position, plus puts and calls.
Changes since Q2 2026
16 new, 7 added to, 13 trimmed, 14 exited, 37 unchanged. By estimated dollars.
New positions (16)
| LTGO Latigo Biotherapeutics, Inc. · Inc Com | 3.60M | New | $60.1M |
| ETRA Electra Therapeutics, Inc. | 2.61M | New | $29.4M |
| OBX Obsidian Therapeutics, Inc. | 1.48M | New | $20.4M |
| MANE Veradermics, Incorporated | 45,000 | New | $5.5M |
| IRD Opus Genetics, Inc. | 969,605 | New | $4.7M |
| RZLT Rezolute, Inc. | 935,000 | New | $3.9M |
| ACHV Achieve Life Sciences, Inc. | 412,654 | New | $3.3M |
| PCOR Procore Technologies, Inc. | 64,030 | New | $3.3M |
| ZURA Zura Bio Limited | 735,000 | New | $3.1M |
| PYXS Pyxis Oncology, Inc. | 1.00M | New | $2.3M |
Added to (7)
Trimmed (13)
| SPCX Space Exploration Technologies Corp. | 923,218 | -34.0% | -$71.7M |
| DELL Dell Technologies Inc. | 19,342 | -41.3% | -$7.3M |
| VRDN Viridian Therapeutics, Inc. | 100,000 | -61.5% | -$3.3M |
| CRVS Corvus Pharmaceuticals, Inc. | 358,600 | -41.1% | -$2.9M |
| ARTV Artiva Biotherapeutics, Inc. | 529,542 | -39.4% | -$2.5M |
| CGEM Cullinan Therapeutics, Inc. | 1.40M | -9.1% | -$2.1M |
| PVLA Palvella Therapeutics, Inc. | 23,003 | -36.6% | -$1.8M |
| MPLT MapLight Therapeutics, Inc. | 556,371 | -23.8% | -$1.8M |
| SGMT Sagimet Biosciences Inc. | 1.13M | -10.7% | -$1.3M |
| CMPX Compass Therapeutics, Inc. | 3.15M | -13.0% | -$488.8K |
Exited (14)
| COF Capital One Financial Corporation | 119,757 | Exited | -$24.0M |
| EYPT EyePoint, Inc. | 762,594 | Exited | -$10.9M |
| RYTM Rhythm Pharmaceuticals, Inc. | 61,455 | Exited | -$6.8M |
| CMPS COMPASS Pathways Plc · ADR | 450,000 | Exited | -$6.4M |
| RARE Ultragenyx Pharmaceutical Inc. | 182,638 | Exited | -$6.1M |
| ORIC Oric Pharmaceuticals, Inc. | 400,000 | Exited | -$4.3M |
| EVMN Evommune, Inc. | 180,000 | Exited | -$2.4M |
| CABA Cabaletta Bio, Inc. | 714,710 | Exited | -$2.2M |
| CHYM Chime Financial, Inc. | 89,878 | Exited | -$1.8M |
| CNTX Context Therapeutics Inc. | 2.93M | Exited | -$1.6M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
All positions
Search, sort and filter every position, with puts and calls on their own tab. Premium plan.
Every position, puts and calls. Part of Premium.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Any two quarters side by side. Part of Premium.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q3 2026.
Filings
| Filing | ||||||
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 13, 2026 | 13F-HR | 79 | $547.6M | Current | SEC ↗ |
| Q2 2026 | Aug 11, 2026 | 13F-HR | 76 | $664.5M | Current | SEC ↗ |
| Q1 2026 | May 14, 2026 | 13F-HR | 75 | $372.2M | Current | SEC ↗ |
| Q4 2025 | Feb 20, 2026 | 13F-HR/A (restatement) | 80 | $324.0M | Current | SEC ↗ |
| Q4 2025 | Feb 9, 2026 | 13F-HR | 81 | $1.3B | Replaced | SEC ↗ |
| Q3 2025 | Nov 12, 2025 | 13F-HR | 72 | $322.1M | Current | SEC ↗ |
| Q2 2025 | Aug 11, 2025 | 13F-HR | 72 | $309.9M | Current | SEC ↗ |
| Q1 2025 | May 15, 2025 | 13F-HR | 73 | $310.1M | Current | SEC ↗ |
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer